A Phase II Clinical Study of the Efficacy and Safety of Preoperative Sintilimab in Combination With Nab-paclitaxel and Cisplatin in Borderline Resectable Esophageal Squamous Carcinoma
Latest Information Update: 17 Feb 2023
At a glance
- Drugs Cisplatin (Primary) ; Paclitaxel (Primary) ; Sintilimab (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 13 Feb 2023 Status changed from recruiting to completed.
- 15 Sep 2020 New trial record